NAT-528
Phase 2- Indications
- COVID-19, Cytokine release syndrome
Company intelligence / Profile preview
Natrogen Therapeutics International, Inc.
New York, New York, United Statespharmaceutical-technology.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
NTI‑528, an AHR modulator small molecule drug, has reached Phase 2 clinical trials targeting inflammatory bowel diseases. Another compound, Meisoindigo, appears to be under development for severe active ulcerative colitis but has not yet advanced past the pending stage. The company also holds patents on isoindigo derivatives with potential applications in cancer and broader inflammatory conditions.
- Therapeutic areas
- GastroenterologyOncologyImmunology
- Modalities
- Small molecules (notably isoindigo derivatives such as Meisoindigo and NATURA)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Natrogen Therapeutics International, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natrogen Therapeutics International, Inc..